肿瘤内免疫细胞操作作为一种提高癌症疫苗效率的策略。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-12-12 DOI:10.1016/j.trecan.2024.11.007

James Adeosun, Mohammad Omar Faruk Shaikh, Timothy Brauns, Yuki Agarwala, Mark C Poznansky, Yohannes Gemechu

{"title":"肿瘤内免疫细胞操作作为一种提高癌症疫苗效率的策略。","authors":"James Adeosun, Mohammad Omar Faruk Shaikh, Timothy Brauns, Yuki Agarwala, Mark C Poznansky, Yohannes Gemechu","doi":"10.1016/j.trecan.2024.11.007","DOIUrl":null,"url":null,"abstract":"Shortcomings in cancer vaccine development are attributable to weak and transient anti-tumor cellular responses in the tumor microenvironment. This restriction of efficacy may be due to an intratumoral immunosuppressive milieu, consisting of regulatory T cells, M2 macrophages, and myeloid derived suppressor cells. Here, we analyze recent advances and propose future directions in the modulation of cellular state propensities combined with cancer vaccines.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency.\",\"authors\":\"James Adeosun, Mohammad Omar Faruk Shaikh, Timothy Brauns, Yuki Agarwala, Mark C Poznansky, Yohannes Gemechu\",\"doi\":\"10.1016/j.trecan.2024.11.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Shortcomings in cancer vaccine development are attributable to weak and transient anti-tumor cellular responses in the tumor microenvironment. This restriction of efficacy may be due to an intratumoral immunosuppressive milieu, consisting of regulatory T cells, M2 macrophages, and myeloid derived suppressor cells. Here, we analyze recent advances and propose future directions in the modulation of cellular state propensities combined with cancer vaccines.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.11.007\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.11.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症疫苗开发的缺陷是由于肿瘤微环境中微弱和短暂的抗肿瘤细胞反应。这种疗效的限制可能是由于肿瘤内的免疫抑制环境，包括调节性T细胞、M2巨噬细胞和骨髓源性抑制细胞。在这里，我们分析了最近的进展，并提出了未来的方向在细胞状态倾向的调节结合癌症疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency.

Shortcomings in cancer vaccine development are attributable to weak and transient anti-tumor cellular responses in the tumor microenvironment. This restriction of efficacy may be due to an intratumoral immunosuppressive milieu, consisting of regulatory T cells, M2 macrophages, and myeloid derived suppressor cells. Here, we analyze recent advances and propose future directions in the modulation of cellular state propensities combined with cancer vaccines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.